Can a three-drug cocktail shrink advanced bile-duct tumors?
NCT ID NCT07719738
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether combining bevacizumab (a blood-vessel growth blocker) with nab-paclitaxel and an oral chemotherapy called S-1 can shrink tumors in people with advanced biliary tract adenocarcinoma that has worsened after initial treatment. About 32 participants will receive the drug combination in 21-day cycles. The main goal is to see how many patients experience tumor shrinkage, while also tracking side effects and survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bevacizumab plus nab-paclitaxel and tegafur gimeracil oteracil potassium capsule (S-1)
- What this could lead to
- If effective, this combination could offer a new second-line treatment option for people with advanced biliary tract cancer who have not responded to initial therapy.
- What could go wrong
- This is a small, single-arm phase 2 trial, so results may not be generalizable. The combination may cause significant side effects, and there is no control group to compare against.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital
Beijing, 100021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.